{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:51:46Z","timestamp":1776358306403,"version":"3.51.2"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijbiomac.2025.147057","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T06:30:09Z","timestamp":1755930609000},"page":"147057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["NRG1 fusion glycoproteins in cancer progression \u2013 Structural mechanisms and therapeutic potential: A review"],"prefix":"10.1016","volume":"323","author":[{"given":"Zhe","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huike","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bohan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingtong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.147057_bb0005","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc3947","article-title":"The emerging complexity of gene fusions in cancer","volume":"15","author":"Mertens","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0010","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trecan.2024.01.009","article-title":"Fusion genes in pancreatic tumors","volume":"10","author":"Gkountakos","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0015","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1158\/1078-0432.CCR-19-0160","article-title":"Detection of NRG1 gene fusions in solid tumors","volume":"25","author":"Jonna","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0020","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-19-0191","article-title":"NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma","volume":"25","author":"Jones","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0025","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","article-title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents","volume":"31","author":"Laskin","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2023.08.034","article-title":"HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: implications for HER2-HER3-specific versus pan-HER targeting strategies","volume":"19","author":"Udagawa","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0035","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41571-025-01008-y","article-title":"Emerging importance of HER3 in tumorigenesis and cancer therapy","volume":"22","author":"Garrett","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0040","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jtho.2021.03.013","article-title":"Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers","volume":"16","author":"Odintsov","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0045","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.trecan.2021.11.003","article-title":"NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis","volume":"8","author":"Nagasaka","year":"2022","journal-title":"Trends in cancer"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0050","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2468-1253(23)00479-X","article-title":"Targeting the EGFR signalling pathway in metastatic colorectal cancer","volume":"9","author":"Napolitano","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40259-016-0205-2","article-title":"HER3 as a therapeutic target in cancer","volume":"31","author":"Karachaliou","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0060","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1158\/1078-0432.CCR-14-0854","article-title":"Molecular pathways: targeting NRG1 fusions in lung cancer","volume":"21","author":"Fernandez-Cuesta","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41392-025-02161-7","article-title":"Oncogenic gene fusions in cancer: from biology to therapy","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0075","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0080","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0085","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jtho.2019.05.015","article-title":"Neuregulin 1 fusion-positive NSCLC","volume":"14","author":"Nagasaka","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188707","article-title":"Oncogenic neuregulin 1 gene (NRG1) fusions in cancer: a potential new therapeutic opportunities","volume":"1877","author":"Zhang","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.mcn.2016.10.008","article-title":"Neuregulin1 alpha activates migration of neuronal progenitors expressing ErbB4","volume":"77","author":"Fornasari","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41380-018-0242-y","article-title":"Isoform-specific cleavage of neuroligin-3 reduces synapse strength","volume":"24","author":"Bemben","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0105","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-025-06385-8","article-title":"Brown adipose tissue alleviates podocyte apoptosis through NRG4 in a male mouse model of diabetic kidney disease","author":"Ding","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0110","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1158\/1078-0432.CCR-07-5133","article-title":"Neuregulins and cancer","volume":"14","author":"Montero","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0014-4827(02)00102-7","article-title":"Neuregulins: functions, forms, and signaling strategies","volume":"284","author":"Falls","year":"2003","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0120","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41586-021-04084-z","article-title":"Structures of the HER2-HER3-NRG1\u03b2 complex reveal a dynamic dimer interface","volume":"600","author":"Diwanji","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0125","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1186\/s12864-024-10723-2","article-title":"Discovery of NRG1-VII: the myeloid-derived class of NRG1","volume":"25","author":"Berrocal-Rubio","year":"2024","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2021.05.011","article-title":"NRG1 fusions: biology to therapy","volume":"158","author":"Liu","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41568-020-00322-0","article-title":"Antitumour immunity regulated by aberrant ERBB family signalling","volume":"21","author":"Kumagai","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0140","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.annonc.2022.08.001","article-title":"Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma","volume":"33","author":"Augustin","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ccell.2018.11.018","article-title":"The ERBB-STAT3 axis drives Tasmanian devil facial tumor disease","volume":"35","author":"Kosack","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0150","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41556-022-00967-z","article-title":"EGFR ligands dictate tumour suppression","volume":"24","author":"Beytagh","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0155","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1158\/2159-8290.CD-18-0368","article-title":"ERBB signaling interrupted: targeting ligand-induced pathway activation","volume":"8","author":"Wilson","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0160","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1158\/1078-0432.CCR-19-1219","article-title":"Detection of NRG1 fusions in solid tumors: rare gold?","volume":"25","author":"Dimou","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102436","article-title":"Beyond HER2: targeting the ErbB receptor family in breast cancer","volume":"109","author":"Drago","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0170","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tips.2024.04.009","article-title":"Emerging paradigms and recent progress in targeting ErbB in cancers","volume":"45","author":"Stoup","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0175","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer - an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0180","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.20.03307","article-title":"Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter registry","volume":"39","author":"Drilon","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13000-024-01438-9","article-title":"Diagnostic potential of NRG1 in benign nerve sheath tumors and its influence on the PI3K-Akt signaling and tumor immunity","volume":"19","author":"Yan","year":"2024","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0190","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41556-019-0352-z","article-title":"HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity","volume":"21","author":"Wu","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0195","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/gutjnl-2018-316039","article-title":"Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis","volume":"68","author":"Li","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","article-title":"Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion","volume":"430","author":"Chaganty","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005119","article-title":"Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer","volume":"10","author":"Waks","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0210","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.21.02772","article-title":"Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast Cancer: primary results of the randomized phase III IMpassion050 trial","volume":"40","author":"Huober","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0215","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0220","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1038\/s41467-023-40349-z","article-title":"Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study","volume":"14","author":"Bian","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0225","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2326-6066.CIR-21-0454","article-title":"Identification of immunogenic MHC class II human HER3 peptides that mediate anti-HER3 CD4(+) Th1 responses and potential use as a Cancer vaccine","volume":"10","author":"Basu","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0230","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.8124","article-title":"Anti-HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma","volume":"46","author":"Asano","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0235","article-title":"A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2","volume":"69","author":"Hassani","year":"2021","journal-title":"Curr. Res. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0240","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1158\/1078-0432.CCR-21-3185","article-title":"Modulation of the estrogen\/erbB2 receptors cross-talk by CDK4\/6 inhibition triggers sustained senescence in estrogen receptor- and ErbB2-positive breast cancer","volume":"28","author":"Vigan\u00f2","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0245","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/endrev\/bnac017","article-title":"Estrogen receptor signaling in the immune system","volume":"44","author":"Chakraborty","year":"2023","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0250","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1038\/s41467-020-17414-y","article-title":"Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer","volume":"11","author":"Terranova-Barberio","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0255","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41467-025-56279-x","article-title":"Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers","volume":"16","author":"Griffiths","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0260","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ccell.2025.02.013","article-title":"Sex hormones, the anticancer immune response, and therapeutic opportunities","volume":"43","author":"Conforti","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0265","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.immuni.2022.05.012","article-title":"Androgen receptor-mediated CD8(+) T cell stemness programs drive sex differences in antitumor immunity","volume":"55","author":"Yang","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0270","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1158\/0008-5472.CAN-22-2405","article-title":"Androgen signaling contributes to sex differences in Cancer by inhibiting NF-\u03baB activation in T cells and suppressing antitumor immunity","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0275","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0280","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12943-024-01978-0","article-title":"A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation","volume":"23","author":"Peng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0285","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/2159-8290.CD-13-0633","article-title":"CD74-NRG1 fusions in lung adenocarcinoma","volume":"4","author":"Fernandez-Cuesta","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0290","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/2159-8290.CD-17-1004","article-title":"Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0295","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11912-025-01640-y","article-title":"NRG1 fusions: the new kid on the block","volume":"27","author":"Gupta","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0300","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1093\/annonc\/mdx523","article-title":"Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer","volume":"28","author":"Jones","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0305","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.jtho.2019.07.022","article-title":"Detection of novel NRG1, EGFR, and MET fusions in lung adenocarcinomas in the Chinese population","volume":"14","author":"Pan","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0310","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.jtho.2017.09.1957","article-title":"Evaluation of RET gene rearrangement by fluorescence in situ hybridization in malignant mesothelioma","volume":"13","author":"Salvi","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0315","first-page":"143","article-title":"NRG1 fusions in NSCLC: being eNRGy conscious","volume":"15","author":"Gupta","year":"2024","journal-title":"Lung Cancer (Auckland, N.Z.)"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0320","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1039\/C4CS00370E","article-title":"Cancer biomarker detection: recent achievements and challenges","volume":"44","author":"Wu","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0325","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0330","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrg.2017.44","article-title":"Reference standards for next-generation sequencing","volume":"18","author":"Hardwick","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0335","first-page":"75","article-title":"Translating cancer genomes and transcriptomes for precision oncology","volume":"66","author":"Roychowdhury","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0340","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.tig.2018.05.008","article-title":"The third revolution in sequencing technology","volume":"34","author":"van Dijk","year":"2018","journal-title":"Trends Genet."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0345","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41569-019-0218-x","article-title":"RNA-based diagnostic and therapeutic strategies for cardiovascular disease","volume":"16","author":"Lu","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0350","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jtho.2018.12.020","article-title":"DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer","volume":"14","author":"Davies","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091579","article-title":"Pre-analytical considerations for successful next-generation sequencing (NGS): challenges and opportunities for formalin-fixed and paraffin-embedded tumor tissue (FFPE) samples","volume":"17","author":"Arreaza","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0360","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbcan.2017.05.005","article-title":"Standardising RNA profiling based biomarker application in cancer-the need for robust control of technical variables","volume":"1868","author":"Stewart","year":"2017","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0365","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115920","article-title":"NRG1 promotes tumorigenesis and metastasis and afatinib treatment efficiency is enhanced by NRG1 inhibition in esophageal squamous cell carcinoma","volume":"218","author":"Hou","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0375","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2020-0379","article-title":"Therapeutic potential of Afatinib in NRG1 fusion-driven solid tumors: a case series","volume":"26","author":"Cadranel","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0380","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.2217\/fon-2021-0855","article-title":"Plain language summary of publication: new information for the potential role of afatinib in treating people with NRG1 gene fusion-positive cancer","volume":"18","author":"Cadranel","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0385","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.jtho.2017.04.025","article-title":"Durable response to afatinib in lung adenocarcinoma harboring NRG1 gene fusions","volume":"12","author":"Gay","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107469","article-title":"Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions","volume":"188","author":"Liu","year":"2024","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0395","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12957-023-03129-z","article-title":"Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report","volume":"21","author":"Nie","year":"2023","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0400","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","article-title":"New and emerging targeted treatments in advanced non-small-cell lung cancer","volume":"388","author":"Hirsch","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0405","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1158\/1078-0432.CCR-20-3555","article-title":"Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes","volume":"27","author":"Estrada-Bernal","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0410","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-023-00736-0","article-title":"Neratinib for HER2-positive breast cancer with an overlooked option","volume":"29","author":"Guo","year":"2023","journal-title":"Mol. Med."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0415","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1158\/1078-0432.CCR-20-3605","article-title":"The anti-HER3 mAb seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions","volume":"27","author":"Odintsov","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0420","doi-asserted-by":"crossref","DOI":"10.1038\/npjsba.2016.34","article-title":"Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)","volume":"3","author":"Schoeberl","year":"2017","journal-title":"npj Syst. Biol. Appl."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0425","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40265-025-02155-3","article-title":"Zenocutuzumab: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0430","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2217\/fon-2023-0824","article-title":"The phase I\/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions","volume":"20","author":"Kim","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0440","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 fusion-positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0445","doi-asserted-by":"crossref","first-page":"e1844","DOI":"10.1002\/onco.13860","article-title":"A phase I, first-in-human study of GSK2849330, an anti-HER3 monoclonal antibody, in HER3-expressing solid tumors","volume":"26","author":"Gan","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0450","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/19420862.2016.1212147","article-title":"Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds","volume":"8","author":"Malm","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0455","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-016-3231-3","article-title":"Phase 1 study of new formulation of patritumab (U3-1287) process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer","volume":"79","author":"Shimizu","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0460","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0465","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0470","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0475","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0480","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0485","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-017-0091-4","article-title":"Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment","volume":"6","author":"Yu","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: an update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0495","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2159-8290.CD-22-0475","article-title":"The great immune escape: understanding the divergent immune response in breast Cancer subtypes","volume":"13","author":"Onkar","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0500","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0505","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/j.jtho.2017.05.014","article-title":"ALK and NRG1 fusions coexist in a patient with signet ring cell lung adenocarcinoma","volume":"12","author":"Muscarella","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0510","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0515","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/JTO.0000000000000381","article-title":"Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene","volume":"10","author":"Kimura","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0520","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neo.2016.02.001","article-title":"Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small cell lung cancer cells","volume":"18","author":"Dong","year":"2016","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0525","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0530","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev-med-062016-050343","article-title":"Basket studies: redefining clinical trials in the era of genome-driven oncology","volume":"69","author":"Tao","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ijbiomac.2025.147057_bb0535","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","article-title":"HER3 is an actionable target in advanced prostate cancer","volume":"81","author":"Gil","year":"2021","journal-title":"Cancer Res."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025076147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025076147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T10:35:52Z","timestamp":1757846152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025076147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":106,"alternative-id":["S0141813025076147"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.147057","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NRG1 fusion glycoproteins in cancer progression \u2013 Structural mechanisms and therapeutic potential: A review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.147057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"147057"}}